Clinical trial
RNF and Betaseron® Tolerability Study
NCT00428584 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00428584 |
|---|---|
| Title | RNF and Betaseron® Tolerability Study |
| Official title | A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum… |
| Acronym | REFORMS |
| Lead sponsor | EMD Serono, Industry |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsing Remitting Multiple Sclerosis (RRMS) |
| Intervention type | Drug |
| Interventions | New Formulation of rebif - human interferon beta-1a, Interferon beta -1b |
| Enrollment | 129 |
| Start date | Dec 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Sep 1, 2009 |
| First posted | Jan 30, 2007 |
| Last update posted | Aug 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: